Ostrum Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ostrum Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-23,085	Closed	-$2.78M	–	654
2024 Q1	$2.78M	Buy	23,085 +4,256	+23%	+$521K	0.22%	145
2023 Q4	$2.32M	Sell	18,829 -3,125	-14%	-$390K	0.2%	164
2023 Q3	$2.84M	Buy	21,954 +2,399	+12%	+$320K	0.26%	110
2023 Q2	$2.42M	Buy	19,555 +17	+0.1%	+$2.29K	0.2%	166
2023 Q1	$2.86M	Buy	+19,538	New	+$2.89M	0.25%	133

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Ostrum Asset Management's JAZZ Position: Q2 2024 in Review

Ostrum Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 23,085 shares — an estimated $2.78M sold.

Ostrum Asset Management first reported a position in JAZZ in Q1 2023 and held it in 5 quarters. The position peaked at $2.86M in Q1 2023. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

Ostrum Asset Management reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Ostrum Asset Management sold 23,085 Jazz Pharmaceuticals shares in Q2 2024, an estimated $2.78M.
Ostrum Asset Management first reported a position in Jazz Pharmaceuticals in Q1 2023 and held it in 5 quarters.
Ostrum Asset Management's Jazz Pharmaceuticals position peaked at $2.86M in Q1 2023.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Ostrum Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.